On December 3, 2024, Haemonetics announced that the company had agreed to sell its whole blood assets (whole blood collection, processing, and filtration solution portfolio) to GVS S.p.A for $67.1 million. GVS, a manufacturer providing filtering solutions for healthcare and life sciences, has agreed to pay $44.6 million upfront. The transaction also includes up to $22.5 million in contingent income payments over the next four years.

01. Sell off whole blood business and focus on plasma field
According to the terms of this agreement, GVS will acquire all proprietary whole blood collection, processing, and filtration solutions from Haemonetics. At the same time, GVS will also take over Haemonetics' manufacturing plant in Covina, California, which produces some of the aforementioned products. In addition, GVS also acquired the relevant equipment and assets of Haemonetics' Boston headquarters located in Tijuana, Mexico.

Previously, Haemonetics had announced plans to terminate its online blood collection business and therefore close the Kvyna factory. Recently, Haemonetics submitted a letter to California's "Worker Adjustment and Retraining Notice" stating that the company will close a facility located in Covina, California. If employees cannot find other positions within the company, about 75 people will face unemployment.

Haemonetics stated in a letter dated October 22nd that employees can seek other jobs within the company. The personnel affected by the factory closure include 26 assembly workers, as well as supervisors of chemical laboratories, warehouses, and production departments, as well as several technicians and engineers. The closure will take effect on December 31st.

This transaction follows Haemonetics' sale of its manufacturing business in Fahado, Puerto Rico to GVS in 2020. The two companies have signed long-term supply and development agreements since that transaction. This agreement grants GVS the exclusive right to manufacture and supply proprietary blood filters produced by Fahado.

Haemonetics expects the transaction to be completed in the first quarter of 2025. The company plans to use the proceeds for general corporate purposes and investment in growth plans. The company stated that its blood center business will continue to manufacture and provide customers with a complete set of blood component separation solutions for automated blood collection.

Chris Simon, President and CEO of Haemonetics, stated, "As part of our long-term plan, we are focused on upgrading our product portfolio to strengthen our leadership position in both commercial and non-commercial plasma markets and expand our market share in high growth hospitals. Our agreement with GVS stems from our long-standing partnership and will ensure a smooth transition for Haemonetics' global whole blood customers while supporting our company's goals

02. In recent years, there has been a large-scale layout in the cardiovascular field
According to data, Haemonetics was founded in 1971 and listed on the New York Stock Exchange in 1991, with its headquarters located in Massachusetts, USA. As a global blood technology company, Haemonetics currently has multiple branches and offices worldwide, with products and services spread across multiple regions such as the Americas, Europe, and Asia. Ranked 63rd in the "2023 Global Medical Device Companies Top 100" released by Medical Design&Outsourcing.
The company's products include blood collection equipment, blood separation and preparation equipment, blood transfusion equipment, automated blood processing systems, etc., which play a crucial role in clinical applications. In addition to the product itself, the company also provides training, consulting, technical support and other services to help medical professionals better apply and understand blood management technology, promoting the continuous development of the medical field. In recent years, Haemonetics has begun to expand its presence in the field of cardiovascular intervention on a large scale.

$510 million enters vascular closure market
In 2021, Cardiva Medical acquired VASCADE MVP, the only vascular closure device approved by the US FDA for use after cardiac ablation, for $510 million. The device includes proprietary foldable disc technology and absorbable collagen patches to achieve hemostasis, eliminating the need for manual compression and reducing walking time by 64%. Encourage patients to wake up and engage in activities a few hours earlier, and significantly reduce discomfort.

$253 million to acquire fiber optic leader
In October 2023, OpSens, a Canadian medical cardiac fiber optic sensor manufacturer, was acquired for $253 million, acquiring the company's flagship product "OptoWire" pressure guide wire. The product adopts advanced fiber optic sensor technology and aims to improve clinical prognosis through fractional flow reserve (FFR) and diastolic pressure ratio (dPR) measurement, to assist clinicians in accurate coronary artery diagnosis, treatment, and result confirmation. The product was approved by the FDA in 2015 and is currently on the market in over 30 countries worldwide, providing diagnosis and treatment for over 150000 patients.

Significant investment, reaching acquisition invitation
In 2023, it also invested $30 million in Vivasure Medical, an Irish vascular closure company, to obtain exclusive acquisition rights for its PerQseal vascular closure device in the future. And reach a takeover offer, once Vivasure Medical reaches a milestone, Haemonetic will acquire Vivasure Medical.

Vivasure Medical has already launched a PerQseal product, and two products, PerQseal+and PerQseal Blue, are currently under development.

The first generation PerQseal is a synthetic implant without sutures and fully absorbable for large caliber arterial vascular puncture. Its intravascular patch seals the blood vessels internally, restoring the arteries to their natural state without leaving any traces of collagen, metal implants, or sutures.

Acquisition of Attune Medical
In April 2024, Haemonetics announced that it had completed the acquisition of Attune Medical, a manufacturer of esophageal cooling devices. The acquisition transaction includes a prepayment of $160 million (approximately RMB 1.16 billion) and partial milestone payments.

The ensoeTM esophageal cooling device under Attune Medical is currently the only FDA approved temperature regulating device for esophageal protection during radiofrequency (RF) cardiac ablation. The product achieved sales of $22 million for Attune Medical in less than a year since its launch last year.

It is reported that ensoeTM is a disposable silicone tube inserted into the esophagus, which controls the temperature of the patient's esophagus by connecting to an external heat exchange device (such as the Blanketrol III medical temperature controller).

During the surgery, ensoeTM will be transported to a core location near the heart, close to major blood vessels and the left atrium. The internal water circulation will effectively reduce or increase the patient's esophageal temperature, maintaining esophageal temperature stability.

Source: http://qixieke.com/Font/index/detailPage.html?id=3281-19